| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $364,367 ) |
| | 2025 | 2025 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R43CA295295 | Fluorescent Biosensors for measuring the signaling kinetics of GPCR ligands that activate G12/13 pathways. | 000 | 1 | NIH | 8/25/2025 | $364,367 |
| | 2025 | 2023 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44AI165188 | Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery | 000 | 2 | NIH | 4/23/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44DA050357 | An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder | 000 | 3 | NIH | 4/2/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $300,000 ) |
| | 2023 | 2023 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44AI165188 | Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery | 000 | 2 | NIH | 5/23/2023 | $300,000 |
| | 2023 | 2020 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44GM125390 | A robust assay for detecting agonist bias in living cells. | 000 | 3 | NIH | 4/28/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $615,386 ) |
| | 2022 | 2022 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44AI165188 | Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery | 000 | 1 | NIH | 5/13/2022 | $300,000 |
| | 2022 | 2022 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44DA050357 | An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder | 000 | 3 | NIH | 1/28/2022 | $315,386 |
| | 2022 | 2020 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44GM125390 | A robust assay for detecting agonist bias in living cells. | 000 | 3 | NIH | 2/11/2022 | $0 |
| | 2022 | 2019 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44DA050357 | An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder | 001 | 1 | NIH | 5/20/2022 | $0 |
| | 2022 | 2018 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44NS082222 | Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | 000 | 5 | NIH | 9/26/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $482,109 ) |
| | 2021 | 2021 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44DA050357 | An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder | 000 | 2 | NIH | 1/26/2021 | $482,109 |
|
| Issue Date FY: 2020 ( Subtotal = $600,181 ) |
| | 2020 | 2020 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44GM125390 | A robust assay for detecting agonist bias in living cells. | 000 | 3 | NIH | 6/24/2020 | $600,181 |
| | 2020 | 2018 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R43NS108817 | Live Cell Assays to Identify and Interrogate Stressed Neurons in Models of Neurodegenerative Disease. | 000 | 1 | NIH | 7/7/2020 | $0 |
| | 2020 | 2018 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44NS082222 | Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | 000 | 5 | NIH | 3/6/2020 | $0 |
| | 2020 | 2018 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44NS082222 | Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | 001 | 5 | NIH | 3/23/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $910,933 ) |
| | 2019 | 2019 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44GM125390 | A robust assay for detecting agonist bias in living cells. | 000 | 2 | NIH | 6/25/2019 | $634,836 |
| | 2019 | 2019 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44DA050357 | An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder | 000 | 1 | NIH | 9/16/2019 | $221,097 |
| | 2019 | 2019 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R43NS108817 | Live Cell Assays to Identify and Interrogate Stressed Neurons in Models of Neurodegenerative Disease. | 000 | 1 | NIH | 4/5/2019 | $55,000 |
| | 2019 | 2019 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44DA050357 | An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder | 001 | 1 | NIH | 9/17/2019 | $0 |
| | 2019 | 2017 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R43GM125390 | A robust assay for detecting agonist bias in living cells. | 000 | 1 | NIH | 11/17/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $406,142 ) |
| | 2018 | 2018 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44NS082222 | Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | 000 | 5 | NIH | 8/13/2018 | $210,309 |
| | 2018 | 2018 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R43NS108817 | Live Cell Assays to Identify and Interrogate Stressed Neurons in Models of Neurodegenerative Disease. | 000 | 1 | NIH | 8/13/2018 | $195,833 |
| | 2018 | 2015 | MONTANA MOLECULAR LLC | 366 GALLATIN PARK DR STE A | BOZEMAN | MT | 59715-7912 | GALLATIN | USA | R44NS082222 | Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | 001 | 3 | NIH | 8/13/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $420,000 ) |
| | 2017 | 2017 | MONTANA MOLECULAR LLC | 347 S FERGUSON AVE | BOZEMAN | MT | 59718-6796 | GALLATIN | USA | R44NS082222 | Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | 002 | 4 | NIH | 9/14/2017 | $227,000 |
| | 2017 | 2017 | MONTANA MOLECULAR LLC | 347 S FERGUSON AVE | BOZEMAN | MT | 59718-6796 | GALLATIN | USA | R43GM125390 | A robust assay for detecting agonist bias in living cells. | 000 | 1 | NIH | 8/15/2017 | $193,000 |
| | 2017 | 2015 | MONTANA MOLECULAR LLC | 347 S FERGUSON AVE | BOZEMAN | MT | 59718-6796 | GALLATIN | USA | R44NS082222 | Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | 000 | 3 | NIH | 1/25/2017 | $0 |
| | 2017 | 2015 | MONTANA MOLECULAR LLC | 347 S FERGUSON AVE | BOZEMAN | MT | 59718-6796 | GALLATIN | USA | R44NS082222 | Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | 001 | 3 | NIH | 9/13/2017 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $582,394 ) |
| | 2015 | 2015 | MONTANA MOLECULAR LLC | 910 TECHNOLOGY BOULEVARD | BOZEMAN | MT | 59718-6850 | GALLATIN | USA | R44NS082222 | Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | 000 | 3 | NIH | 4/16/2015 | $582,394 |
|
| Issue Date FY: 2014 ( Subtotal = $585,457 ) |
| | 2014 | 2014 | MONTANA MOLECULAR LLC | 910 TECHNOLOGY BOULEVARD | BOZEMAN | MT | 59718-6850 | GALLATIN | USA | R44NS082222 | Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | 000 | 2 | NIH | 1/13/2014 | $585,457 |
|
| Issue Date FY: 2011 ( Subtotal = $348,182 ) |
| | 2011 | 2011 | MONTANA MOLECULAR LLC | 910 TECHNOLOGY BOULEVARD | BOZEMAN | MT | 59718-6850 | GALLATIN | USA | R43MH096670 | FAST AND ACCURATE TOOLS FOR MEASURING FLUORESCENCE IN LIVING CELLS | 000 | 1 | NIH | 7/25/2011 | $348,182 |
| | 2011 | 2009 | MONTANA MOLECULAR LLC | 2155 ANALYSIS DRIVE | BOZEMAN | MT | 59718 | GALLATIN | USA | R41NS056830 | A NEW MODULAR TOOL SET FOR LIVE IMAGING AND MANIPULATING THE NERVOUS SYSTEM | 000 | 2 | NIH | 5/23/2011 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $141,714 ) |
| | 2009 | 2009 | MONTANA MOLECULAR LLC | 910 TECHNOLOGY BOULEVARD | BOZEMAN | MT | 59718-6850 | GALLATIN | USA | R41NS056830 | A NEW MODULAR TOOL SET FOR LIVE IMAGING AND MANIPULATING THE NERVOUS SYSTEM | 001 | 2 | NIH | 4/30/2009 | $105,046 |
| | 2009 | 2009 | MONTANA MOLECULAR LLC | 910 TECHNOLOGY BOULEVARD | BOZEMAN | MT | 59718-6850 | GALLATIN | USA | R41NS056830 | A NEW MODULAR TOOL SET FOR LIVE IMAGING AND MANIPULATING THE NERVOUS SYSTEM | 000 | 1 | NIH | 4/21/2009 | $36,668 |
|
| Issue Date FY: 2008 ( Subtotal = $105,046 ) |
| | 2008 | 2008 | MONTANA MOLECULAR LLC | 910 TECHNOLOGY BOULEVARD | BOZEMAN | MT | 59718 | GALLATIN | USA | R41NS056830 | A NEW MODULAR TOOL SET FOR LIVE IMAGING AND MANIPULATING THE NERVOUS SYSTEM | 000 | 1 | NIH | 5/13/2008 | $105,046 |
|
|
